CJC-1295 (No DAC) / GHRP-6 Blend is a research peptide formulation combining two well-studied synthetic peptides frequently examined in growth hormone and endocrine signaling research: CJC-1295 without Drug Affinity Complex (No DAC) and Growth Hormone–Releasing Peptide-6 (GHRP-6). CJC-1295 (No DAC) is a modified growth hormone–releasing hormone (GHRH) analog, while GHRP-6 is a growth hormone secretagogue receptor (GHS-R) agonist originally developed as a hexapeptide. Together, this blend is formulated for laboratory research focused on growth hormone release dynamics, receptor signaling pathways, and metabolic regulation mechanisms.
Prior to the targeted synthesis and study of these peptides, research into growth hormone modulation relied largely on less selective secretagogues and broader hormonal approaches. In controlled research settings, CJC-1295 (No DAC) has been studied for its ability to stimulate endogenous growth hormone release through GHRH receptor activation while maintaining a shorter duration of activity compared to DAC-bound variants. GHRP-6 has been widely researched for its role in ghrelin receptor activation and its effects on growth hormone secretion amplitude and frequency. The combination allows researchers to examine complementary mechanisms involved in pulsatile growth hormone signaling and coordinated pituitary response models.
Currently, the CJC-1295 (No DAC) / GHRP-6 Blend is being investigated for potential applications in metabolic research models, endocrine signaling analysis, recovery-related pathways, and age-associated hormone regulation studies. Additional research continues to explore its role in downstream anabolic signaling, appetite-related hormone interactions, and circadian growth hormone release patterns. Due to the complementary research interest of these peptides, this blend remains a compelling subject for ongoing laboratory investigation.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
BPC-157, TB-500 Blend is a dual-peptide research product formulated for laboratories investigating tissue response signaling, recovery-associated pathways, and connective tissue research models. This blend combines BPC-157 (a body-protection compound peptide sequence studied in gastric and tissue research) with TB-500 (a thymosin-derived peptide fragment frequently referenced in cell migration and repair-context literature).
In research settings, pairing these two peptides is typically used to evaluate how distinct signaling pathways may complement one another within the same protocol. Investigators may incorporate this blend when they want a single variable that represents both local tissue integrity signaling and broader remodeling or cellular movement markers. Each lot is supported by documentation intended to align with research-grade sourcing standards and internal quality management workflows.
BPC-157, TB-500 Blend – Research Specifications:
| Format | Lyophilized peptides (blend) |
| Active Compounds | BPC-157 + TB-500 (thymosin-derived fragment) |
| Purity / Identity | Research-grade; refer to Certificate of Analysis (COA) for lot-specific data |
| Source | Chemical synthesis |
| Appearance | Lyophilized powder |
| Storage Conditions | Store sealed in a cool, dry environment, protected from heat, light, and moisture. Maintain lot integrity per laboratory SOPs. |
| Research Use Only | Supplied exclusively for laboratory research use. Not for human consumption, clinical use, or veterinary applications. |
BPC-157 and TB-500 are frequently discussed within the same “repair and recovery” research conversation, but they are explored for different reasons. BPC-157 is commonly referenced in gastrointestinal integrity and soft tissue signaling literature, while TB-500 is often discussed in relation to actin dynamics, cell migration signaling, and broader tissue remodeling frameworks.
From a study-design standpoint, the blend can be useful when investigators want to examine how multiple recovery-associated signaling inputs behave under controlled conditions, without introducing a long list of separate variables. In comparative designs, researchers may also reference single-compound pages like BPC 157 and Thymosin Beta 4 (a related thymosin category) to clarify pathway focus and differentiate endpoints.
Some labs also place recovery studies into broader performance systems, especially where resilience and output are tracked alongside tissue integrity. In those cases, it can be helpful to contextualize recovery signaling with cellular energy variables such as NAD or mitochondrial signaling compounds like MOTS-C, depending on the experiment’s scope.
Important Research Notice: Nordsci products are supported by lot-level analytical documentation. Certificates of Analysis are available to support internal audits, method alignment, and reproducibility across study phases.
THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE OR CONDITION.
This blend is often used in research programs examining connective tissue markers, collagen-related signaling, and structural integrity variables. Investigators may track markers tied to matrix turnover, fibroblast signaling, or time-based tissue response patterns under controlled protocols.
TB-500 is frequently discussed in the context of cellular movement and remodeling-related signaling. When paired with BPC-157, researchers may evaluate whether the blend provides a broader signal footprint in tissue-recovery models than a single compound alone.
Many labs use blends to simplify experimental design while still evaluating multi-pathway effects. In these studies, investigators may compare a blend against single inputs to assess pathway overlap, signal dominance, or confounding risks.
In advanced experimental designs, the blend may be considered alongside broader recovery category tools such as the Wolverine Stack or related formulations like Repair and Recovery Capsules, particularly when protocols evaluate multiple recovery endpoints. Clear definition of primary endpoints and controls is essential to preserve interpretability.
As a lyophilized blend, BPC-157, TB-500 Blend should be handled using standard laboratory best practices and documented per internal SOPs. Maintain storage integrity, minimize moisture exposure, and record any preparation steps as required by the research environment.
Protocol Design Considerations: Tissue-response research can be highly sensitive to baseline tissue status, activity variables, model selection, and time-course design. Standardizing these inputs strengthens reproducibility and improves cross-cohort comparability.
Note: The information above is provided as a high-level research reference only. All experimental use must be conducted by qualified personnel in appropriately equipped facilities, following applicable regulations and institutional policies.
Each lot of BPC-157, TB-500 Blend is accompanied by a Certificate of Analysis documenting compound identity and quality parameters. COAs are intended to support protocol documentation, internal quality assurance, and reproducibility across research cohorts.
When sourcing multi-compound recovery research peptides, laboratories should prioritize clear labeling, lot traceability, and documentation availability. Nordsci Peptides provides research-grade products designed to integrate cleanly into compliance-focused procurement and study documentation workflows.
IMPORTANT: BPC-157, TB-500 Blend is supplied exclusively for laboratory research use. Not approved for human consumption or therapeutic use. Researchers are responsible for compliance with all applicable laws, regulations, and institutional guidelines.
Browse Nordsci Products
Expandable categories. Full product glossary included for internal discovery and cross-navigation.
